Stockreport

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

Aurinia Pharmaceuticals Inc - Common Shares  (AUPH) 
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.auriniapharma.com
PDF VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES 42.9% of VOS subjects vs 18.4% of Restasis [Read more]